Health & bio
Phase 3 ATTAIN-MAINTAIN shows sustained weight loss vs. placebo
The phase 3 ATTAIN-MAINTAIN trial demonstrated orforglipron's superiority over placebo in maintaining weight loss after semaglutide or tirzepatide injection plateaus. Most common side effects: nausea, vomiting, diarrhea, constipation, indigestion.
Primary sources · 1